gadoliniumallergia

Gadolinium allergy, or hypersensitivity to gadolinium-based contrast agents (GBCAs), refers to adverse immune or nonimmune reactions attributed to the use of these agents in diagnostic imaging, most commonly magnetic resonance imaging (MRI). GBCAs are chelated forms of gadolinium designed to reduce toxicity, but a small number of patients experience reactions ranging from mild to severe.

Clinical presentation can be immediate, occurring within minutes of administration, or delayed, developing hours to days later. Immediate reactions may include hives, itching, facial swelling, nausea, throat tightness, wheezing, and in rare cases anaphylaxis. Delayed reactions can present as fever, rash, or arthralgia. true IgE-mediated gadolinium allergy is considered rare; many reported reactions may reflect nonallergic hypersensitivity or other factors related to the contrast medium.

Incidence varies by agent and population but is generally low. Risk factors for gadolinium reactions include a prior reaction to GBCAs, a history of atopy or asthma, and, in some cases, higher exposure or specific formulations. Kidney impairment is more closely linked to nephrogenic systemic fibrosis with older, nonmacrocyclic GBCAs, rather than to immediate allergic reactions, but kidney function is still considered when selecting a GBCA.

Diagnosis is based on history and clinical presentation; skin testing for GBCAs has limited standardization and utility in all settings. Management of a suspected reaction follows emergency protocols: stop the infusion, assess severity, and treat with epinephrine for anaphylaxis, plus antihistamines or corticosteroids as indicated. After a reaction, re-exposure to GBCAs is generally avoided unless essential; allergist consultation and careful choice of alternative agents or imaging methods are advised. When re-exposure is necessary, some centers may use premedication or a different GBCA with lower risk, though effectiveness varies.